Unknown Analyst

[indiscernible] CEO, Mike Carrel; and CFO, Angie Wirick. We're going to do a 30-minute fireside chat, but thanks, everyone, for joining us.

Unknown Analyst

I guess, Mike, Angie, starting out at a high level on the '26 guide and some of the growth drivers in the business. You delivered 15% revenue growth in 2025. You're guiding 12% to 14% in '26. As a management team, you've consistently met or exceeded your guidance. So how should investors think about the setup for the year? What's giving you confidence in the range? And do you feel there's an appropriate level of conservatism baked in given kind of the macro environment?

Angela Wirick
Chief Financial Officer

I'm going to start with your last question first. Yes, I think there's appropriate conservatism. Our philosophy, and we've said this many times, is we want to put guidance out there that we feel really comfortable not just being able to meet, but that there's a pathway to beat.

And when I look at the setup for 2026, I'd say the big thing that we say is innovation is really driving revenue growth in 2026. Continuation of a lot of the product launches that we started in 2025. So in our pain management business, the cryoSPHERE MAX Probe. In our appendage management business, we have 2 product launches, the FLEX-Mini and the PRO-Mini. So those both give us a shot on goal.

I think in each one of these new product launches, you are talking about driving both growth in volume, but then also pricing uplift because there's new innovation built